Opaleye Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Opaleye Management’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-563,500	Closed	-$6.13M	–	59
2023 Q4	$6.13M	Sell	563,500 -20,500	-4%	-$154K	1.63%	18
2023 Q3	$4.7M	Sell	584,000 -41,000	-7%	-$341K	1.53%	16
2023 Q2	$6.79M	Sell	625,000 -140,000	-18%	-$1.2M	1.62%	14
2023 Q1	$5.28M	Sell	765,000 -61,200	-7%	-$384K	1.58%	20
2022 Q4	$3.29M	Buy	+826,200	New	+$4.06M	1.14%	26
2022 Q3	–	Sell	-68,900	Closed	-$333K	–	51
2022 Q2	$333K	Buy	+68,900	New	+$419K	0.15%	43

Other funds holding MRNS

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Opaleye Management's MRNS Position: Q1 2024 in Review

Opaleye Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2024, closing a stake of 563,500 shares — an estimated $6.13M sold.

Opaleye Management first reported a position in MRNS in Q2 2022 and held it in 6 quarters. The position peaked at $6.79M in Q2 2023. 112 funds tracked by Wall St. Rank hold MRNS as of Q1 2024.

Opaleye Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2024 after selling out during the quarter.
Opaleye Management sold 563,500 Marinus Pharmaceuticals, Inc shares in Q1 2024, an estimated $6.13M.
Opaleye Management first reported a position in Marinus Pharmaceuticals, Inc in Q2 2022 and held it in 6 quarters.
Opaleye Management's Marinus Pharmaceuticals, Inc position peaked at $6.79M in Q2 2023.
112 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2024.

Based on Opaleye Management's 13F filing for Q1 2024, filed 15 May 2024.